Thursday, 23 March 2017
Latest news
Main » Nektar Opioid Drug Does Well In Study (NKTR, EGLT)

Nektar Opioid Drug Does Well In Study (NKTR, EGLT)

20 March 2017

During the double-blind, randomized treatment phase, average pain scores increased more in the placebo arm than in the NKTR-181 arm at week 12 (1.46 for placebo vs. 0.92 for NKTR-181; P = 0.0019). Shares in San Francisco-based Nektar were trading at $19.94 this morning, up more than 28 percent from Friday's closing price. Covering sell-side analysts are estimating company growth for next year to be 30.40%. For the quarter, shares have been noted at 27.26%. Wells Fargo & Company MN now owns 115,326 shares of the biopharmaceutical company's stock worth $1,981,000 after buying an additional 6,604 shares during the last quarter.

For the Current Quarter, 9 analyst are projecting the mean EPS to be $-0.06/share. Shares of the Company are trading above their 50-day moving average by 47.91%.

Shaun Marsh, Peter Handscomb help Australia draw third Test against India
India is in a strong position heading into the final day of the third Test in Ranchi after declaring at 9-603 on Sunday. They were further down two wickets after a set Smith and Matt Renshaw got out in a space of four balls before lunch.

Rex Energy Corporation (NASDAQ:REXX) topped its 52-week high price of $1.44 on April 12, 2016 and 52-Week Low Price of $0.23 on Nov 15, 2016.

Rex Energy Corporation (NASDAQ:REXX) is now showing 77.8% EPS growth this Quarter. During the same quarter in the prior year, the firm earned ($0.40) EPS.

The UK Is Set To Officially Begin The Brexit Process
Once the draft negotiating guidelines have been accepted, the European Commission will legally recommend the starting of talks. Notification comes 279 days after the referendum of June 23 past year delivered a 52%-48% majority in favour of withdrawal.

Assuming positive Phase 3 efficacy results from the current SUMMIT-07 trial, we plan to out-license NKTR-181 to a company that has a strong presence and long-term commitment in the pain market. Piper Jaffray Companies set a $25.00 price target on Nektar Therapeutics and gave the stock a "buy" rating in a research report on Monday, December 12th. The company's stock is moving with the distance from SMA 50 of 15.51 Percent while the distance from 200-day simple moving average for the stock is 4.4 percent. The stock most recently traded at $19.00. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are created to enable the development of new molecular entities that target known mechanisms of action.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Wednesday, March 1st. This showed the surprise of -7.7% in the last quarter earnings. According to their observations and findings, the stock could provide a high EPS of $-0.28/share and a Low EPS of $-0.54/share.

Edamame sold at Publix recalled in North Carolina over listeria fears
Most healthy individuals suffer only high fever, severe headache, stiffness, nausea, abdominal pain or diarrhea for a short time. An Edamame product has been recalled in 33 states due to fears it may be contaminated with potentially fatal listeria bacteria.

Nektar president and CEO, Howard Robin, commented, "As a new molecule, NKTR-181 has a highly differentiated profile with the potential to be one of the most important advancements in pain medicine". At the end of this 12-week blinded trial period, placebo pain scores rose by 1.46, while NKTR-181 patients only rose by 0.92.

Nektar Opioid Drug Does Well In Study (NKTR, EGLT)